Drugs / Onabotulinum Toxin Type A
Onabotulinum Toxin Type A
also known as
BTX-A · Botox · BotoxA · Botulinum toxin type-A · Botulinum toxin-A · Botulinum-A neurotoxin · botulinum-A toxin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06928246 | Jul 2025 → Dec 2026 expected | atopic eczema | Daniel Kaplan | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01421719 | Feb 2009 → May 2011 | Parkinson disease | Stanford University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04940143 | Aug 2020 → Jul 2021 | cerebral palsy spastic hemiplegic | Marmara University | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01374191 Comparator | Jan 2015 → May 2017 | neuroma | Southern Illinois University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01309802 Comparator | May 2011 → May 2016 | Raynaud disease | Southern Illinois University | Completed | No outcome recorded |
Press releases naming this drug 36 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onabotulinum Toxin Type A | “Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy” NCT01421719 ↗ |
| Known as | Botox | “Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points” NCT04940143 ↗ |
| Known as | BotoxA | “botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease” NCT01421719 ↗ |
| Known as | Botulinum toxin type-A | “Botulinum toxin type-A (Onabotulinum toxin type-A)” NCT04940143 ↗ |
| Known as | Botulinum toxin-A | “Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points” NCT04940143 ↗ |
| Known as | Botulinum-A neurotoxin | “Botulinum-A neurotoxin (BTX-A) has been shown in pilot trials to be quite effective in reducing overactive bladder symptoms” NCT01421719 ↗ |
| Known as | botulinum-A toxin | “intra-detrusor injections of botulinum-A toxin (BTX-A) in 20 male or female patients with Parkinson's disease and neurogenic overactive bladder” NCT01421719 ↗ |
| Known as | BTX-A | “Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy” NCT01421719 ↗1“botulinum toxin type A (Btx-A) injections for Raynaud's phenomenon” NCT01309802 ↗ |
| Modality | Protein / enzyme biologic | “botulinum toxin type A (Btx-A) injections for Raynaud's phenomenon” NCT01309802 ↗ |
| Route | Other | “Btx-A injections” NCT01309802 ↗ |